香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 - 1 - 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年九月十五日 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局（「國家藥監局」）有關葡萄糖酸鈣氯化鈉注射液 （100ml:1g/0.8g）的藥品生產註冊批件，屬於化學藥品第3類，視同通過一致性評價。葡萄糖酸 鈣氯化鈉注射液主要用於治療急性低鈣血症、鎂中毒及氟中毒，並與本集團於二零二五年六月 四日獲批的葡萄糖酸鈣氯化鈉注射液（100ml:2g/675mg）及二零二五年七月十八日獲批的葡萄 糖酸鈣注射液(10ml:1g)共同構建了鈣製劑產品系列。 董事局亦欣然公告，本集團已取得國家藥監局有關嗎啉硝唑氯化鈉注射液(100ml:0.5g/0.9g)的 藥品生產註 ...

格隆汇9月12日丨石四药集团(02005.HK)发布公告，2025年9月12日耗资275.110万港元回购90万股，回 购价格每股3.05-3.06港元。 石四药集团(02005.HK)9月12日耗资275.110万港元回购90万股 石四药集团(02005.HK)9月11日耗资 1814.33万港元回购600万股 相关事件 ...

智通财经APP讯，石四药集团(02005)发布公告，于2025年9月12日斥资275.1万港元回购90万股。 ...

表格類別： 股票 狀態： 新提交 公司名稱： 石四藥集團有限公司 呈交日期： 2025年9月12日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

Group 1 - On September 11, 28 Hong Kong-listed companies conducted share buybacks, totaling 16.42 million shares and an amount of 639 million HKD [1][2] - Tencent Holdings repurchased 874,000 shares for 550 million HKD, with a year-to-date total buyback amount of 50.50 billion HKD [1][2] - Hang Seng Bank repurchased 210,000 shares for 24.88 million HKD, with a year-to-date total buyback amount of 69.60 million HKD [1][2] - Stone Four Pharmaceutical Group repurchased 6 million shares for 18.14 million HKD, with a year-to-date total buyback amount of 8.42 million HKD [1][2] Group 2 - The highest buyback amount on September 11 was from Tencent Holdings at 550 million HKD, followed by Hang Seng Bank at 24.88 million HKD [1][2] - In terms of share quantity, Stone Four Pharmaceutical Group had the highest buyback volume with 6 million shares, followed by Yongda Automobile and Puhua Heshun with 1.5 million and 1.35 million shares respectively [1][2] - China Sanjiang Chemical's recent buyback was its first of the year, while Tencent Holdings has conducted multiple buybacks totaling 50.50 billion HKD this year [2]

Summary of Key Points Core Viewpoint - Multiple companies conducted share buybacks on September 11, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1][2]. Company Buyback Details - Tencent Holdings (00700) repurchased 874,000 shares for a total of 550 million, with a year-to-date total of 54.758 million shares, representing 0.596% of its total share capital [2]. - Hang Seng Bank (00011) repurchased 210,000 shares for 24.882 million, with a year-to-date total of 6.12 million shares, representing 0.325% of its total share capital [2]. - Stone Four Pharmaceutical Group (02005) repurchased 6 million shares for 18.1433 million, with a year-to-date total of 22.6 million shares, representing 0.766% of its total share capital [2]. - MGM China (02282) repurchased 1 million shares for 16.2463 million, with a year-to-date total of 18.6274 million shares, representing 0.490% of its total share capital [2]. - Other notable companies include: - China Hongqiao (01378) with 100,500 shares repurchased for 2.4636 million, totaling 149 million shares, representing 1.590% of its total share capital [2]. - Weigao Group (01066) with 429,200 shares repurchased for 2.4248 million, totaling 10.4532 million shares, representing 2.315% of its total share capital [2]. - Coolpad Group (02369) with 924,000 shares repurchased for 1.2036 million, totaling 1.2519 million shares, representing 3.057% of its total share capital [2].

Company News - New天绿色能源 (00956.HK) reported a power generation of 9.8787 million MWh in the first eight months, an increase of 10.55% year-on-year; August's power generation was 784.8 thousand MWh, up 23.53% year-on-year [2] -远洋集团 (03377.HK) recorded a contract sales amount of 16.44 billion yuan in the first eight months, a decrease of 25.9% year-on-year; August's contract sales were approximately 1.7 billion yuan, down 17.5% year-on-year [2] - 合生创展集团 (00754.HK) reported a contract sales amount of approximately 9.902 billion yuan in the first eight months, a decrease of 15.6% year-on-year; August's contract sales were about 334 million yuan, down 38.4% year-on-year [2] - 越秀交通基建 (01052.HK) reported a cumulative toll revenue of approximately 603 million yuan for the Guangzhou North Second Ring Expressway in the first seven months, a decrease of 0.7% year-on-year [2] - 华油能源 (01251.HK) entered into a financing lease agreement with Zhongguancun Science and Technology Leasing [2] - 日清食品 (01475.HK) plans to invest 30.68 million yuan to acquire land in Zhuhai for new production facilities [2] - 鲁大师 (03601.HK) subscribed to a structured deposit product from China Merchants Bank, involving 50 million yuan [2] - 越秀地产 (00123.HK) plans to obtain a term loan financing of 200 million HKD [2] - 康宁杰瑞制药-B (09966.HK) had its new drug application for KN026 (Anituzumab injection) accepted by the National Medical Products Administration [2] Buyback Activities - 腾讯控股 (00700.HK) repurchased 874,000 shares at a cost of 550 million HKD, with repurchase prices ranging from 624 to 633 HKD [2] - 汇丰控股 (00005.HK) spent approximately 108 million HKD to repurchase about 1.041 million shares, with repurchase prices between 102.8 and 104.3 HKD [2] - 恒生银行 (00011.HK) repurchased 210,000 shares at a cost of approximately 24.882 million HKD, with repurchase prices from 117.9 to 119.2 HKD [2] - 百胜中国 (09987.HK) repurchased about 57,900 shares at a cost of approximately 20.2 million HKD, with repurchase prices between 347 and 351.8 HKD [2] - 石四药集团 (02005.HK) repurchased 6 million shares at a cost of approximately 18.143 million HKD, with repurchase prices ranging from 2.98 to 3.04 HKD [2] - 美高梅中国 (02282.HK) repurchased 1 million shares at a cost of 16.2463 million HKD, with repurchase prices between 16.04 and 16.45 HKD [3] Power Generation Data - 中广核新能源 (01811.HK) reported a power generation of approximately 12,850.5 GWh in the first eight months, a decrease of 1.6% year-on-year; August's power generation was 1,543.7 GWh, down 5.7% year-on-year [4]

（原标题：石四药集团(02005.HK)9月11日回购600.00万股，耗资1814.33万港元） | 日期 | 回购股数 （万股） | 回购最高价 （港元） | 回购最低价 （港元） | 回购金额 （万港元） | | --- | --- | --- | --- | --- | | 2025.09.11 | 600.00 | 3.040 | 2.980 | 1814.33 | | 2025.06.05 | 540.00 | 2.800 | 2.770 | 1509.58 | | 2025.06.04 | 345.00 | 2.850 | 2.790 | 972.54 | | 2025.06.02 | 755.00 | 2.780 | 2.610 | 2098.38 | | 2025.04.02 | 280.00 | 3.440 | 3.330 | 958.82 | | 2025.01.16 | 50.00 | 3.210 | 3.190 | 160.11 | | 2025.01.15 | 160.00 | 3.230 | 3.190 | 513.20 | | 2025.01.14 | 70.00 | 3.25 ...

格隆汇9月11日丨石四药集团(02005.HK)发布公告，2025年9月11日耗资1814.33万港元回购600万股，回 购价格每股2.98-3.04港元。 ...

石四药集团(02005)发布公告，于2025年9月11日，该公司斥资1814.33万港元回购600万股。 ...